Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | GLA | P06280 | 5/20 | 0.50 |
| ▸ | RECQL | P46063 | 4/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 6/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11834751 | 0.75 | CTSV (0.44) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL3032558 | 0.74 | KDM4E (0.80) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL4474609 | 0.73 | MDM2 (0.62) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL9538000 | 0.72 | NPC1 (0.44) | KDM4EGLAPKMALDH1A1GAA | |
| SCHEMBL11835107 | 0.71 | KDM4E (0.58) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL11834747 | 0.71 | CTSV (0.41) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL11840596 | 0.71 | CRHBP (0.48) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL9701575 | 0.70 | MDM2 (0.59) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL10810736 | 0.69 | PDE3B (0.60) | KDM4EMEN1KMT2AGLARECQL | |
| SCHEMBL9538008 | 0.69 | MDM2 (0.42) | KDM4EGLAALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| EP-1308441-B1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | EISAI R&D MAN CO LTD (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-3948903-A | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins | PARKE, DAVIS & COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | KDM4E 768/4885MEN1 3490/4885KMT2A 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.